How We Use AI to Deliver Innovation Faster for Patients
We uses artificial intelligence (AI) to accelerate the development of innovative medicines and vaccines with one objective: delivering treatments to patients sooner.
AI technologies support our teams in:
- Faster target discovery
- Advanced drug design modeling
- More efficient clinical trial design
- Improved patient screening
- Digital patient population analysis
Our AI Centre of Excellence in Canada
Toronto is home to one of Sanofi’s five Global Digital Hubs. Over 150 team members support the incubation, scaling, and deployment of digital and AI solutions across 90+ countries.
As part of an integrated global network, the team works toward halving the time from scientific discovery to the delivery of innovative treatments.
Unique to Canada, our digital teams are co-located with key business functions, enabling closer collaboration and rapid scaling of solutions globally.
A New Milestone in Our AI Journey
In 2026, Sanofi announced a $294 million investment in its AI Centre of Excellence in Toronto. This expansion will create 50 new high-skilled roles in artificial intelligence and machine learning, strengthening Sanofi’s long-term commitment to Ontario and its position as a leading hub for innovation.
Leading AI in Biopharma
Sanofi is at the forefront of artificial intelligence in pharmaceutical research, with our Canadian teams playing a pivotal role in advancing the field.
Our experts share cutting-edge research at leading global conferences, including NeurIPS and ICML.
Through this work, we are reinforcing Canada’s leadership in Artificial Intelligence in the Global stage.
Commitment to Responsible AI
We advance AI responsibly through a robust governance framework that balances innovation and risk management.
Our digital teams develop AI-enabled solutions to optimize product yield across manufacturing sites, enhancing efficiency and helping reduce our environmental footprint.